Core Insights - Viva Biotech is enhancing its AI-driven drug discovery capabilities by optimizing the Proteina-Complexa model to design mini-binders targeting ActRIIA, a receptor important for muscle wasting and lean mass imbalance [1][5] - The collaboration with NVIDIA emphasizes the "Lab-in-the-Loop" workflow, integrating computational design with high throughput protein production and biophysical evaluation to expedite drug discovery [2][4] - The use of AI techniques for sequence selection has led to more efficient mini-binder designs, allowing exploration of new chemical spaces and improving design specificity at reduced costs and time compared to traditional methods [3][4] Company Overview - As a leading contract research organization (CRO), Viva Biotech specializes in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), utilizing computational modeling, generative AI, and extensive wet lab capabilities [4] - The company aims to strengthen its AI algorithm development and enhance its drug discovery processes to deliver high-quality solutions for partners in the evolving AI-driven drug discovery landscape [4]

Core Viewpoint - iBio, Inc. has announced a public offering of pre-funded warrants and accompanying Series G and Series H warrants, aiming to raise approximately $50 million to advance its preclinical programs and support working capital needs [1][3][4]. Offering Details - The offering includes pre-funded warrants for 71,540,000 shares and Series G warrants for 35,770,000 shares, with a combined public offering price of $0.699 per unit [1][3]. - The estimated gross proceeds from the offering are expected to be around $50 million before deducting underwriting discounts and commissions [3]. - The offering is expected to close on or about August 22, 2025, subject to customary closing conditions [1]. Warrant Specifications - Pre-funded warrants are immediately exercisable until fully exercised, while Series G and Series H warrants will have an exercise price of $0.70 per share [2]. - Series G warrants will expire either 30 trading days after a significant trial initiation announcement or five years from issuance [2]. Use of Proceeds - iBio plans to use the net proceeds to advance its preclinical cardiometabolic programs, including IBIO-610 and IBIO-600, and to fund working capital and other corporate purposes [4]. Underwriters - Leerink Partners is the lead bookrunner for the offering, with LifeSci Capital and Oppenheimer & Co. as bookrunning managers [5].